


SUMMARY

Influenza activity in the Army population remained stable from Week 7 to Week 8, and RSV activity continues to decrease. Six influenza-associated hospitalizations were reported during surveillance Week 8. Nationwide, influenza activity remains elevated, with 13.9% of specimens tested by clinical laboratories being positive for influenza A or B, according to the Centers for Disease Control and Prevention (CDC). As a reminder, seasonal influenza spreads rapidly and easily. Getting vaccinated is the best way to prevent exposure and further spread of influenza.

DEMOGRAPHICS

Positive Respiratory Specimen Results from Army MTFs by Age Group and Beneficiary Status, Week 8



AD: Two hundred and seventy-three positive respiratory specimens were collected from active duty (AD) service members (SMs) during Week 8; 62.6% (n=171) of the positive specimens were collected from SMs 18 – 29 years of age.


Non-AD: Five hundred and fifty-eight positive respiratory specimens were collected from non-AD individuals during Week 8; 56.8% (n=317) of the positive specimens were collected from individuals under 18 years of age and 12.0% (n=67) from individuals who are 18 – 29 years old.

*Non-AD=All individuals that are not active duty service members.

The age and beneficiary status of some cases were not available. Therefore, all calculations involving these variables were conducted using only available data. Differences in total results, and age- and beneficiary status-specific results may be noted throughout the report.

INFLUENZA-ASSOCIATED HOSPITALIZATIONS

Army Influenza-Associated Hospitalizations Reported in DRSi by Onset Week



Six influenza-associated hospitalizations with an onset date in Week 8 were reported to the Disease Reporting System internet (DRSi). The season total thus far is 142 hospitalizations. The Week 8 average during the 2018 – 2023 seasons was 9 hospitalizations (with an average of 169 hospitalizations reported from the start of the season through Week 8).

The DRSi does not capture cases older than 65 years old for influenza-associated hospitalizations.


*Data from the 2020–2021 and 2021–2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.

Data are preliminary and subject to change.


Disclaimer: The mention of any non-federal entity and/or its products is for informational purposes only, and not to be construed or interpreted, in any manner, as federal endorsement of that non-federal entity or its products.

Questions?
Email DCPH-A-DEP

INFLUENZA A ACTIVITY - ARMY



RSV ACTIVITY - ARMY



Of the 4,294 specimens tested for influenza A during Week 8, 9.8% (n=419) were positive.

Of the 2,970 specimens tested for RSV during Week 8, 2.5% (n=74) were positive. RSV activity continues to decrease.


*Data from the 2020–2021 and 2021–2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.

	Week 5	Week 6	Week 7	Week 8	Season Total	
Army MTF Laboratory Results, 2023-24	Adenovirus	13	16	14	12	276
	Enterovirus	53	55	39	39	988
	Influenza A	541	479	452	419	10,044
	Influenza B	349	326	304	271	4,044
	Parainfluenza	6	21	16	16	262
	RSV	106	115	76	74	5,754
	Negative	4,246	3,584	3,866	3,520	79,247
	Total	5,314	4,596	4,767	4,351	100,615


Of the 4,351 specimens tested during Week 8, 19.1% (n=831) were positive for any type of respiratory illness. Influenza A accounted for 50.4% (n=419) of the positive results, influenza B accounted for 32.6% (n=271), RSV accounted for 8.9% (n=74), enterovirus accounted for 4.7% (n=39), parainfluenza accounted for 1.9% (n=16) and adenovirus accounted for 1.4% (n=12). Additionally, the reported number of specimens tested decreased 8.7% from Week 7 to Week 8. Significantly more tests for influenza have been conducted this season compared to past seasons; 99,320 specimens have been tested for influenza A so far this season compared to the average of 64,741 specimens during the same time period in 2018-2023*.

INFLUENZA-LIKE ILLNESS (ILI) ACTIVITY - UNITED STATES

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2023-2024 Season



Percentage of Outpatient Visits for Respiratory Illness Reported by The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2023-24 Season and Selected Previous Seasons




Nationwide in Week 8 (CDC's Week 9), incident ILI activity was 4.1%; this is above the national baseline of 2.9%. Additionally, a total of 81,237 specimens were tested for influenza by select clinical laboratories and submitted to the CDC; 11,294 (13.9%) were positive. Influenza A accounted for 56.9% (n=6,428) of the total positive specimens.

Locations providing Week 8 laboratory data as of 28 February 2024: Camp Zama, Carlisle Barracks, Ft. Belvoir, Ft. Bliss, Ft. Campbell, Ft. Cavazos, Ft. Carson, Ft. Drum, Ft. Eisenhower, Ft. Eustis, Ft. Gregg-Adams, Ft. Huachuca, Ft. Irwin, Ft. Jackson, Ft. Johnson, Ft. Knox, Ft. Leavenworth, Ft. Leonard Wood, Ft. Lewis, Ft. Liberty, Ft. Meade, Ft. Moore, Ft. Novosel, Ft. Riley, Ft. Sam Houston, Ft. Sill, Ft. Stewart, Ft. Wainwright, Korea, Landstuhl Regional Medical Center, Redstone Arsenal, Tripler Army Medical Center, the U.S. Military Academy at West Point, and Walter Reed National Military Medical Center.


Proportion of Influenza A Positive Specimens by Week and Medical Readiness Command, 2023–2024 as Compared to 2018–2023*

Medical Readiness Command - East




Week 8			
Age Group	AD	Non-AD	Season Total
< 18	0	35	1,186
18–29	43	16	750
30–39	14	12	547
40–49	8	6	370
50–59	1	9	284
60+	0	6	309
Total	66	84	3,446

Medical Readiness Command - Europe (Landstuhl Regional Medical Center)




Week 8			
Age Group	AD	Non-AD	Season Total
< 18	0	3	43
18–29	1	1	23
30–39	0	0	18
40–49	0	1	17
50–59	0	0	8
60+	0	0	5
Total	1	5	114

Medical Readiness Command - Pacific



Week 8			
Age Group	AD	Non-AD	Season Total
< 18	0	11	352
18–29	24	3	447
30–39	7	3	253
40–49	2	0	102
50–59	0	2	56
60+	0	3	102
Total	33	22	1,312

Medical Readiness Command - West




Week 8			
Age Group	AD	Non-AD	Season Total
< 18	0	43	1,807
18–29	52	22	1,309
30–39	23	14	820
40–49	4	15	471
50–59	0	15	351
60+	0	20	409
Total	79	129	5,167

*2018–2019, 2019–2020, and 2022–2023 influenza seasons. Data from the 2020–2021 and 2021–2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.


Number of Positive Influenza A Specimens by Region and Duty Status

Region	Week 5		Week 6		Week 7		Week 8	
	AD	Non-AD	AD	Non-AD	AD	Non-AD	AD	Non-AD
MRC-East	69	138	63	125	71	97	66	84
MRC-Europe	1	4	2	3	0	2	1	5
MRC-Pacific	11	26	15	21	13	20	33	22
MRC-West	74	218	52	198	77	172	79	129

Positive Respiratory Specimen Results from Army MTFs by Age Group and Beneficiary Status, Week 8




Army Influenza-Associated Hospitalizations Reported in DRSi by Onset Week




*2018-2019, 2019-2020, and 2022-2023 influenza seasons. Data from the 2020-2021 and 2021-2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.

Proportion of Positive Influenza A Specimens for U.S. Army, 2023-2024




*2018–2019, 2019–2020, and 2022–2023 influenza seasons. Data from the 2020–2021 and 2021–2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.

Proportion of Positive RSV Specimens for U.S. Army, 2023-2024



*2018–2019, 2019–2020, and 2022–2023 influenza seasons. Data from the 2020–2021 and 2021–2022 influenza seasons are not included in comparison calculations due to the unusually low incidence of influenza.

Percentage of Outpatient Visits for Respiratory Illness Reported by
The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet),
Weekly National Summary, 2023-24 Season and Selected Previous Seasons



Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2023-2024 Season

